Davis Polk advised the joint book-running managers in connection with the $180 million initial public offering of common stock of Beam Therapeutics Inc. The common stock is listed on the Nasdaq Global Select Market under the symbol “BEAM.”
Based in Cambridge, Massachusetts, Beam Therapeutics is developing precision genetic medicines through base editing. Founded by leading scientists in CRISPR gene editing, Beam Therapeutics is pursuing therapies for serious diseases using its proprietary base editing technology, which can make precise edits to single base pairs in DNA and RNA.
The Davis Polk corporate team included partners Deanna L. Kirkpatrick and Yasin Keshvargar and associates Yoojin Nairn-Kim, Daniel Chao and Edward Peck. Partner David R. Bauer and associate Hilary Smith provided intellectual property and technology advice. Partner Po Sit and associate Adam R. Brownstone provided tax advice. Counsel Marcie A. Goldstein provided FINRA advice. Members of the Davis Polk team are based in the New York and Northern California offices.